We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

219 hedge funds and large institutions have $497M invested in Aurinia Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more call options, than puts

Call options by funds: $12.9M | Put options by funds: $7.42M

21% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 28

2% more funds holding

Funds holding: 214 → 219 (+5)

6% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 64

1% less capital invested

Capital invested by funds: $504M → $497M (-$6.99M)

2.22% less ownership

Funds ownership: 45.65% → 43.43% (-2.2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
219
Holders Change
+5
Holders Change %
+2.34%
% of All Funds
2.88%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
34
Increased
68
Reduced
64
Closed
28
Calls
$12.9M
Puts
$7.42M
Net Calls
+$5.48M
Net Calls Change
-$1.18M

Top Buyers

Rank Fund Capital Flow
1
RAM
Readystate Asset Management
Illinois
+$5.27M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.45M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$3.1M
4
JF
Jump Financial
Illinois
+$2.72M
5
RHJA
Rice Hall James & Associates
California
+$2.61M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$27M
2
Goldman Sachs
Goldman Sachs
New York
-$9.56M
3
BlackRock
BlackRock
New York
-$8.55M
4
N
Nuveen
North Carolina
-$7.85M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
CWM
151
CIBC World Markets
New York
$123K -$122K -15,276 -51%
TSS
152
Two Sigma Securities
New York
$122K -$131K -16,285 -53%
OC
153
Oppenheimer & Co
New York
$114K +$80 +10 +0.1%
BNP Paribas Financial Markets
154
BNP Paribas Financial Markets
France
$110K +$25.6K +3,191 +32%
Pictet Asset Management
155
Pictet Asset Management
Switzerland
$105K – – –
BWM
156
BCS Wealth Management
Tennessee
$103K – – –
AIP
157
Ameritas Investment Partners
Nebraska
$102K -$11.4K -1,428 -11%
US Bancorp
158
US Bancorp
Minnesota
$102K +$152 +19 +0.2%
QC
159
Quantessence Capital
New York
$100K +$94.8K +11,822 New
B
160
Bailard
California
$99.1K +$93.8K +11,700 New
Wealth Enhancement Advisory Services
161
Wealth Enhancement Advisory Services
Minnesota
$98.6K +$17.9K +2,238 +21%
VPIM
162
Vanguard Personalized Indexing Management
California
$92.5K +$87.5K +10,919 New
Mackenzie Financial
163
Mackenzie Financial
Ontario, Canada
$90.8K – – –
AIM
164
Aigen Investment Management
New York
$90.4K +$85.5K +10,671 New
ACM
165
ADAR1 Capital Management
Texas
$84.7K +$80.2K +10,000 New
AWS
166
Atria Wealth Solutions
New York
$75.9K – – –
CLOS
167
Compagnie Lombard Odier SCmA
Switzerland
$67.8K – – –
BTI
168
Blue Trust Inc
Georgia
$55.7K -$4.83K -603 -8%
Group One Trading
169
Group One Trading
Illinois
$53.3K -$440K -54,905 -90%
Walleye Capital
170
Walleye Capital
New York
$44.4K +$5.05K +630 +14%
Mirae Asset Global Investments
171
Mirae Asset Global Investments
South Korea
$44.2K +$4.99K +623 +14%
MCM
172
MAI Capital Management
Ohio
$41.3K – – –
AB
173
Amalgamated Bank
New York
$40K – – –
T
174
Tidemark
California
$36.8K – – –
GFM
175
GF Fund Management
China
$31.1K – – –
5 6
7
8 9

AUPH Hedge Fund Activity: Q2 2025 in Review

219 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2025, worth a combined $497M — down 1.4% from $504M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AUPH positions and 28 closed out — a net gain of 6 holders — while 68 added to existing stakes and 64 trimmed.

The largest buyer was Readystate Asset Management, opening a new position worth an estimated $5.27M. The largest seller was Armistice Capital, cutting an estimated $27M.

  • 219 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2025, up from 214 in Q1 2025.
  • Funds reported $497M of Aurinia Pharmaceuticals stock for Q2 2025, down 1.4% quarter-over-quarter.
  • 34 funds opened new Aurinia Pharmaceuticals positions in Q2 2025 and 28 closed out, a net change of +6 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q2 2025 was Readystate Asset Management, an estimated $5.27M added.
  • The largest Aurinia Pharmaceuticals seller in Q2 2025 was Armistice Capital, an estimated $27M sold.

Based on aggregated 13F filings for Q2 2025.